false 0001042074 0001042074 2020-05-11 2020-05-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 11, 2020

 

CymaBay Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

001-36500

 

94-3103561

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

7575 Gateway Blvd., Suite 110

Newark, CA 94560

(Address of principal executive offices)

(510) 293-8800

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12 (b) of the Act:

Title of Each Class

 

Trading

Symbol(s)

 

Name of Each Exchange

on Which Registered

Common Stock, par value $0.0001 per share

 

CBAY

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 

 


Item 2.02 Results of Operations and Financial Condition.

On May 11, 2020, CymaBay Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020 and certain corporate highlights. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by this reference.

The information in this report, including the exhibit hereto, shall be deemed “filed” under the Securities Exchange Act of 1934.

Item 8.01 Other Events.

The information set forth in Item 2.02 is incorporated by reference here.

Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1 is deemed to be filed, rather than furnished, under the Securities Exchange Act of 1934.

Exhibit
No.

   

Description

         
 

99.1

   

Press release dated May 11, 2020

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CymaBay Therapeutics, Inc.

     

By:

 

/s/ Sujal Shah

Name:

 

Sujal Shah

Title:

 

President and Chief Executive Officer

Dated: May 11, 2020

Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Cymabay Therapeutics Charts.
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Cymabay Therapeutics Charts.